Diabetes and Cognitive Deficits in Chronic Schizophrenia: A Case-Control Study

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Han, Mei ^a,b   Huang, Xu Feng ^a,b   Chen, Da Chun ^c   Xiu, Meihong ^c   Kosten, Thomas R ^c,d   Zhang, Xiang Yang ^c,d  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Schizophrenia Research Institute   (Australia)

^c PEKING UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; METFORMIN; PERPHENAZINE; REPAGLINIDE; RISPERIDONE; SULPIRIDE;

ADULT; AGED; ARTICLE; ATTENTION; CASE CONTROL STUDY; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPTH PERCEPTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITIVE AND NEGATIVE SYNDROME SCALE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; ATTENTION; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84879269575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066299     Document Type: Article

References (57)

1. Keefe RS, (2007) Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 68Suppl 14: 8-13.
2. Leifker FR, Bowie CR, Harvey PD, (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 115: 82-87.
3. Couture SM, Penn DL, Roberts DL, (2006) The functional significance of social cognition in schizophrenia: a review. Schizophrenia Bulletin 32Suppl 1: S44-63.
4. Condray R, Yao JK, (2011) Cognition, dopamine and bioactive lipids in schizophrenia. Frontiers in Bioscience 3: 298-330.
5. Vaz-Serra A, Palha A, Figueira ML, Bessa-Peixoto A, Brissos S, et al. (2010) [Cognition, social cognition and functioning in schizophrenia]. Acta Med Port 23: 1043-1058.
6. Bowie CR, Harvey PD (2005) Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 28: 613-633, 626.
7. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, et al. (2006) Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. European Archives of Psychiatry & Clinical Neuroscience 256: 442-451.
8. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE, (2005) Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophrenia Research 78: 27-34.
9. Shean GD, (2007) Recent developments in psychosocial treatments for schizophrenic patients. Expert Rev Neurother 7: 817-827.
10. Allen KV, Frier BM, Strachan MWJ, (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. European Journal of Pharmacology 490: 169-175.
11. Kumar R, Looi J, Raphael B, (2009) Type 2 diabetes mellitus, cognition and brain in aging: A brief review. Indian J Psychiatry 51Suppl 1: S35-38.
12. Manschot SM, Brands AMA, van der Grond J, Kessels RPC, Algra A, et al. (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55: 1106-1113.
13. Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, et al. (2007) Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 50: 2388-2397.
14. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, et al. (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age & Ageing 33: 355-361.
15. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P, (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurology 5: 64-74.
16. Ruis C, Biessels GJ, Gorter KJ, van den Donk M, Kappelle LJ, et al. (2009) Cognition in the early stage of type 2 diabetes. Diabetes Care 32: 1261-1265.
17. Dickinson D, Gold JM, Dickerson FB, Medoff D, Dixon LB, (2008) Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 49: 123-131.
18. van den Berg E, Kessels RP, Kappelle LJ, de Haan EH, Biessels GJ, (2006) Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. Drugs Today (Barc) 42: 741-754.
19. Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, et al. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 192: 406-411.
20. Rouillon F, Sorbara F, (2005) Schizophrenia and diabetes: epidemiological data. European Psychiatry: the Journal of the Association of European Psychiatrists 20Suppl 4: S345-348.
21. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, et al. (2000) Prevalence and Correlates of Diabetes in National Schizophrenia Samples. Schizophrenia Bulletin 26: 903-912.
22. Guo X, Zhang Z, Zhu W, Lian N, Lu H, et al. (2011) Cognitive functioning in schizophrenia with or without diabetes. Zhong Nan da Xue Xue Bao Yi Xue Ban = Journal of Central South University. Medical Sciences. 36: 724-727.
23. Crosby-Nwaobi R, Sivaprasad S, Forbes A, (2012) A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes. Diabetes Research & Clinical Practice 96: 101-110.
24. Umegaki H, Iimuro S, Shinozaki T, Araki A, Sakurai T, et al. (2012) Risk factors associated with cognitive decline in the elderly with type 2 diabetes: baseline data analysis of the Japanese Elderly Diabetes Intervention Trial. Geriatrics & gerontology international 12Suppl 1: 103-109.
25. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 15: 539-553.
26. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
27. Duff K, Humphreys Clark JD, O'Bryant SE, Mold JW, Schiffer RB, et al. (2008) Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers. Archives of Clinical Neuropsychology 23: 603-612.
28. Abe Y, Namba H, Zheng Y, Nawa H, (2009) In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: Implication of ErbB receptors for dopaminergic neurons. Neuroscience 161: 95-110.
29. Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, et al. (2009) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a Screening Test in Chinese: Reliability and Validity Chinese Mental Health Journal. 28: 865-869.
30. World Health, Organization (1998) Obesity: preventing and managing the global epidemic. In: Organization WH (Ed.), Report of a WHO Consultation on Obesity. World Health Organization, Geneva, 3-5.
31. Han M, Huang X-F, Chen DC, Xiu MH, Hui L, et al. (2012) Gender differences in cognitive function of patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 39: 358-363.
32. Antonova E, Sharma T, Morris R, Kumari V, (2004) The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophrenia Research 70: 117-145.
33. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. (2009) Common variants conferring risk of schizophrenia. Nature 460: 744-747.
34. Walters JTR, Corvin A, Owen MJ, Williams H, Dragovic M, et al. (2010) Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Archives of General Psychiatry 67: 692-700.
35. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B, (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biological Psychiatry 48: 381-388.
36. du Bois TM, Deng C, Han M, Newell KA, Huang XF, (2009) Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. European Neuropsychopharmacology 19: 256-265.
37. Messier C, (2005) Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. [Review] [33 refs]. Neurobiology of Aging 1: 26-30.
38. Papanikolaou Y, Palmer H, Binns MA, Jenkins DJ, Greenwood CE, (2006) Better cognitive performance following a low-glycaemic-index compared with a high-glycaemic-index carbohydrate meal in adults with type 2 diabetes. Diabetologia 49: 855-862.
39. Heckers S, Konradi C, (2010) Hippocampal pathology in schizophrenia. Current Topics in Behavioral Neurosciences 4: 529-553.
40. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, et al. (2008) Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nature Neuroscience 11: 309-317.
41. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, et al. (2011) Hippocampal interneurons are abnormal in schizophrenia. Schizophrenia Research 131: 165-173.
42. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R, (1987) Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes 36: 597-601.
43. De Silva PN, (2011) Does the association with diabetes say more about schizophrenia and its treatment?-the GLUT hypothesis. Med Hypotheses 77: 529-531.
44. Baskin DG, Figlewicz DP, Woods SC, Porte D Jr, Dorsa DM, (1987) Insulin in the brain. Annual Review of Physiology 49: 335-347.
45. Miller SL, Celone K, DePeau K, Diamond E, Dickerson BC, et al. (2008) Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proceedings of the National Academy of Sciences of the United States of America 105: 2181-2186.
46. Stone WS, Hsi X, (2011) Declarative memory deficits and schizophrenia: problems and prospects. Neurobiology of Learning & Memory 96: 544-552.
47. Heinrichs RW, (2005) The primacy of cognition in schizophrenia. American Psychologist 60: 229-242.
48. Hall J, Whalley HC, Marwick K, McKirdy J, Sussmann J, et al. (2010) Hippocampal function in schizophrenia and bipolar disorder. Psychological Medicine 40: 761-770.
49. Convit A, (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiology of Aging 26Suppl 1: 31-35.
50. Sota TL, Heinrichs RW, (2003) Sex differences in verbal memory in schizophrenia patients treated with "typical" neuroleptics. Schizophrenia Research 62: 175-182.
51. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, et al. (1999) Glucose-induced increase in memory performance in patients with schizophrenia. Schizophrenia Bulletin 25: 321-335.
52. Daban C, Amado I, Bourdel M-C, Loo H, Olie J-P, et al. (2005) Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. Journal of Psychiatric Research 39: 391-398.
53. Woodward ND, Purdon SE, Meltzer HY, Zald DH, (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 8: 457-472.
54. Stevens A, Schwarz J, Schwarz B, Ruf I, Kolter T, et al. (2002) Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics. Psychopharmacology 160: 299-306.
55. Zhang XY, Chen da C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR, (2012) Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry 73(7): 1025-1033.
56. Randolph C, Tierney MC, Mohr E, Chase TN, (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. Journal of Clinical & Experimental Neuropsychology: Official Journal of the International Neuropsychological Society 20: 310-319.
57. Cheng Y, Wu WY, Wang JQ, Feng W, Wu XW, et al. (2011) Reliability and validity of the Repeatable Battery for the Assessment of Neuropsychological Status in community-dwelling elderly. Achives of Medical Science 7: 850-857.